Anabelle Chinea
Overview
Explore the profile of Anabelle Chinea including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
142
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kwon M, Gomez-Centurion I, Oarbeascoa G, Torres M, Perez Martinez A, Suarez-Lledo M, et al.
Transplant Cell Ther
. 2024 Jun;
30(10):1033.e1-1033.e8.
PMID: 38871055
Invasive fungal infections (IFI) pose a significant complication after hematopoietic stem cell transplantation (HSCT). Isavuconazole (ISV) is a new generation azole with a favourable adverse effect and interaction profile approved...
2.
Gomez-Centurion I, Gallardo Morillo A, Perez Martinez A, Cabrero Calvo M, Chinea A, Gonzalez L, et al.
Transplant Cell Ther
. 2024 Jun;
30(9):914.e1-914.e8.
PMID: 38851323
Sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) is a life-threatening complication after both autologous and allogeneic hematopoietic stem cell transplantation (HSCT). However, its characterization after haploidentical HSCT (haplo-HSCT) with post-transplantation cyclophosphamide (PT-Cy)...
3.
Chumbita M, Puerta-Alcalde P, Yanez L, Angeles Cuesta M, Chinea A, Espanol-Morales I, et al.
Microbiol Spectr
. 2023 Jun;
11(4):e0067423.
PMID: 37367629
Optimal coverage of Pseudomonas aeruginosa is challenging in febrile neutropenic patients due to a progressive increase in antibiotic resistance worldwide. We aimed to detail current rates of resistance to antibiotics...
4.
Bailen R, Alenda R, Herruzo-Delgado B, Acosta-Fleitas C, Valles A, Esquirol A, et al.
Front Immunol
. 2023 Jun;
14:1165759.
PMID: 37304258
Background: Donor-specific antibodies (DSAs) are IgG allo-antibodies against mismatched donor HLA molecules and can cause graft failure (GF) in the setting of haploidentical hematopoietic stem cell transplantation (haplo-HSCT). Our aim...
5.
Chumbita M, Puerta-Alcalde P, Yanez L, Angeles Cuesta M, Chinea A, Espanol Morales I, et al.
J Antimicrob Chemother
. 2022 Apr;
77(7):2017-2023.
PMID: 35466357
Objectives: To describe current resistance to the β-lactams empirically recommended in the guidelines in bloodstream infection (BSI) episodes caused by Gram-negative bacilli (GNB). Methods: Retrospective, multicentre cohort study of the...
6.
Hernandez-Boluda J, Pereira A, Zinger N, Gras L, Martino R, Nikolousis E, et al.
Bone Marrow Transplant
. 2022 Apr;
57(6):1051.
PMID: 35361897
No abstract available.
7.
Bailen R, Pascual-Cascon M, Guerreiro M, Lopez-Corral L, Chinea A, Bermudez A, et al.
Transplant Cell Ther
. 2022 Feb;
28(4):204.e1-204.e10.
PMID: 35108627
Post-transplantation cyclophosphamide (PTCY) effectively prevents graft-versus-host disease (GVHD) after unmanipulated HLA-haploidentical hematopoietic stem cell transplantation (HSCT) and achieves low rates of GVHD in HLA-identical transplantation. To compare the outcomes of...
8.
Hernandez-Boluda J, Pereira A, Zinger N, Gras L, Martino R, Nikolousis E, et al.
Bone Marrow Transplant
. 2022 Jan;
57(3):416-422.
PMID: 35066569
Allogeneic hematopoietic cell transplantation (allo-HCT) is the only curative treatment for patients with myeloid/lymphoid neoplasm (MLN) with FGFR1 rearrangement, but data on overall results are limited. We report on the...
9.
Bailen R, Vicario J, Solan L, Sanchez-Vadillo I, Herrera P, Calbacho M, et al.
Front Immunol
. 2021 Jun;
12:674658.
PMID: 34093576
Background: Donor specific antibodies (DSAs) can be responsible for graft failure (GF) in the setting of mismatched hematopoietic stem cell transplantation (HSCT). The aim of our study is to report...
10.
Pinana J, Martino R, Garcia-Garcia I, Parody R, Morales M, Benzo G, et al.
Exp Hematol Oncol
. 2020 Sep;
9:21.
PMID: 32864192
Background: Prognostic factors of poor outcome in patients with hematological malignancies and COVID-19 are poorly defined. Patients And Methods: This was a Spanish transplant group and cell therapy (GETH) multicenter...